Corgenix signs CMO deal with EDP Biotech

Diagnostics outfit Corgenix is upping its stake in the contract manufacturing game, inking a deal with EDP Biotech to produce a colon cancer test. Under the 10-year deal, Corgenix will manufacture ColoMarker, EDP's blood test for early stage colon cancer. The agreement follows Corgenix's May expansion of its contract services business, an effort to pad revenue and capitalize on the increase in demand for in vitro diagnostics. More

Suggested Articles

The platform uses wearables to continuously collect clinical data from study participants and applies machine learning to analyze the data.

St. Jude, Microsoft and DNAnexus have created a data-sharing and analysis platform to help accelerate pediatric cancer research.

The money will be used to expand its footprint in both China and the U.S., including a new R&D operation in Boston.